In vitro antifungal activity of pneumocandin L-743,872 against a variety of clinically important molds.
about
Zygomycetes in human diseaseNovel perspectives on mucormycosis: pathophysiology, presentation, and management.Mucormycosis, pseudallescheriasis, and other uncommon mold infectionsHospital-acquired phaeohyphomycosis due to Exserohilum rostratum in a child with leukemiaInfections caused by Scedosporium spp.Mucormycosis in a renal transplant recipient: case report and comprehensive review of literatureIn vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungiEfficacy of FK463, a new lipopeptide antifungal agent, in mouse models of disseminated candidiasis and aspergillosisSynergistic antifungal activities of bafilomycin A(1), fluconazole, and the pneumocandin MK-0991/caspofungin acetate (L-743,873) with calcineurin inhibitors FK506 and L-685,818 against Cryptococcus neoformansEfficacy of the echinocandin caspofungin against disseminated aspergillosis and candidiasis in cyclophosphamide-induced immunosuppressed miceIn vitro susceptibility testing methods for caspofungin against Aspergillus and Fusarium isolatesComparison of In vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeastsAntifungal peptides: novel therapeutic compounds against emerging pathogensManagement and Novel Adjuncts of Necrotizing Soft Tissue Infections.In vitro activity of caspofungin against Candida albicans biofilms.In vitro interaction of terbinafine with itraconazole against clinical isolates of Scedosporium prolificans.Compartmental pharmacokinetics of the antifungal echinocandin caspofungin (MK-0991) in rabbits.Correlation between antifungal susceptibilities of Coccidioides immitis in vitro and antifungal treatment with caspofungin in a mouse model.Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia.Evaluation of broth microdilution testing parameters and agar diffusion Etest procedure for testing susceptibilities of Aspergillus spp. to caspofungin acetate (MK-0991).Influences of methodological variables on susceptibility testing of caspofungin against Candida species and Aspergillus fumigatusThe Cryptococcus neoformans MAP kinase Mpk1 regulates cell integrity in response to antifungal drugs and loss of calcineurin functionScedosporium prolificans osteomyelitis in an immunocompetent child treated with voriconazole and caspofungin, as well as locally applied polyhexamethylene biguanideBlack Molds and Melanized Yeasts Pathogenic to HumansPurpureocillium lilacinum as a cause of cavitary pulmonary disease: a new clinical presentation and observations on atypical morphologic characteristics of the isolateCombination treatment of invasive fungal infections.A review of clinical experience with newer antifungals in childrenFusarium keratitis: genotyping, in vitro susceptibility and clinical outcomes.Susceptibility testing and molecular classification of Paecilomyces spp.Right buttock rash for thirty years in a patient from ChinaInterlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus speciesCombination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosisIn vitro activity of anidulafungin against selected clinically important mold isolatesA glucan synthase FKS1 homolog in cryptococcus neoformans is single copy and encodes an essential function.In vitro interaction of caspofungin acetate with voriconazole against clinical isolates of Aspergillus spp.Comparative evaluation of disk diffusion with microdilution assay in susceptibility testing of caspofungin against Aspergillus and Fusarium isolatesCombination echinocandin-polyene treatment of murine mucormycosis.
P2860
Q24514527-03D6105C-AD1F-44E2-A2E6-59AC933A8DCDQ24530554-F92AF559-12CE-4B70-BB56-70C6F9ADA47EQ24603297-DD50B5D9-CD86-4952-BFC0-C24AF856CBA5Q24652237-A904CCB8-78DD-4658-872E-296838788828Q24657691-8D8BCF20-FACF-4467-8634-AF1100EF04F4Q26860727-A6AD6993-7B0A-4018-B41E-E4739F1DD8CCQ28343817-B0F09D98-95B6-4178-A5CC-F609093B5708Q28343919-5F8B10C9-BC22-433D-B63D-42DE50863805Q28343929-EC756B4C-EEA2-41CD-8C48-371CC81A037BQ28344589-4A837C33-F502-41CC-944A-D9DBE43B5EE2Q28345261-3F3C9D60-4F5C-4ECE-B2A0-7ABC7ADB756EQ28368930-42DFD91B-F325-4600-AF1E-A0E8353DCF30Q28369443-3991B1B8-2DCC-40BE-B35E-312EE512668AQ30234954-6425EA49-524D-418F-8852-CAC0D5B85D4CQ31114513-F36BC5CE-7FE2-4DCE-98C7-E98FAB89B86DQ33978865-D3F4C24A-CD62-42C8-8D44-7DBF20D10CDFQ33981480-35F58524-7242-474D-BBA9-8A5A894D0662Q33982369-B7937FE6-4292-481E-8F15-84C1BC945BBBQ34104748-C6BF0132-B9B4-4F7B-9609-3E75960E231AQ34749364-22585C21-2D47-4304-859F-40195E9D561EQ35102477-A2BD1C19-D9D0-41B5-A081-2C8CA0E55381Q35128586-EF2EE59C-9823-4AC4-A3F2-BD561CB263C3Q35194598-CD731C2A-BCFF-449E-95B1-90665E440BF4Q35408323-C14DC400-333B-4EC3-BE10-FDDCEF231AAEQ35942921-0981C502-1FE1-4853-95B2-0233A8861491Q36011378-BADF9B25-D71C-410B-8470-54FC568884BCQ36290698-2FAADA26-0277-41FD-8887-AD5254EBF08BQ36756216-1181DB16-3CC9-4711-B747-30D74A8A20A9Q36804026-9D9D686B-A038-485E-A005-D56768893ECEQ37147056-CD8D36ED-6CC5-4251-847F-C6D0E93C8688Q37157546-60D27EC2-333C-4266-A372-4AC2F1642B14Q37475959-DC7701D3-6E4F-4C11-BA7E-789B09850B2AQ37734590-8CB2231C-93D5-4B79-AFBA-BBF184006C6FQ39493735-3BC58EC3-0893-4631-8465-14870648FBDDQ39652771-6BA4FD05-68FF-43CB-AF2C-D1842474C02CQ39652840-2707CEF1-3157-4907-A411-DC278E4B1614Q41904884-4BEAC447-8D46-4A1D-89AD-26B7A43DCCAD
P2860
In vitro antifungal activity of pneumocandin L-743,872 against a variety of clinically important molds.
description
1997 nî lūn-bûn
@nan
1997 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
1997 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
name
In vitro antifungal activity o ...... of clinically important molds.
@ast
In vitro antifungal activity o ...... of clinically important molds.
@en
type
label
In vitro antifungal activity o ...... of clinically important molds.
@ast
In vitro antifungal activity o ...... of clinically important molds.
@en
prefLabel
In vitro antifungal activity o ...... of clinically important molds.
@ast
In vitro antifungal activity o ...... of clinically important molds.
@en
P2093
P1476
In vitro antifungal activity o ...... of clinically important molds.
@en
P2093
J R Perfect
M Del Poeta
W A Schell
P2860
P304
P407
P577
1997-08-01T00:00:00Z